FIRALIS S.A. appoints Alain FOURNELLE as Chief Financial Officer



Huningue, France, July 31st, 2019 - Firalis S.A (“Firalis”), a developer of biomarker-based products and provider of biomarker services announces the appointment of Alain Fournelle as new Chief Financial Officer.

Alain has three decades of financial expertise in various fields of financial recovery, due diligence and mergers & acquisitions as consultant at E&Y but also as administrative and financial director in service and industrial companies, finally as Chief Financial Officer of companies such as BVA, Saphymo, BDO.

In his new assignment as the Chief Financial Officer of Firalis S.A., Alain will strengthen and grow more visible the company’s business strategy, by providing to present and future investors with in-depth financial, as well as administrative and structural insights and projections.

“We are more than pleased to welcome Alain on board, a proven expertise in financial administration, joining us just at the right time, as we consolidate our group for future development.” said Pr. Huseyin FIRAT, the Group CEO of Firalis.

“I’m truly excited to join such an enthusiastic Group at such a crucial time. I believe that with the synergy we already started to establish with my experience and the capabilities of Firalis, we will bring tremendous advancement for the development of Group financials and overall business.” Alain Fournelle said, on his first official day at Firalis.



Firalis Group is a biotechnology company developing novel biomarkers and biomarker-based tools for precision medicine. Firalis Group is active in the field of drug safety, cardiovascular, inflammatory, neurodegenerative and autoimmune diseases, and has been awarded with several national and international prizes for its innovative approaches. Firalis Group is certified ISO 13485 (GMP compliant) and ISO 9001 for the development and production of CE-marked assays, certified NF S 96-900 for its biobank and accredited ISO 17025 (GCLP compliant) for testing laboratory. Additional information is available at


Contact press:

Alexis Rufenacht - +33 (0) 3 89 910 111 -

Comments are closed.